Namsco Corp Ordinary Shares NAMS 深 沪
已收盘 08-01 16:00:00 美东时间
21.28
-0.530
-2.43%
华盛通- 最 高22.01
- 今 开21.48
- 成交量 55.79万股
- 最 低 21.135
- 昨 收 21.81
- 总市值 23.83亿
- 52周最高 27.29
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 14.06
- 委 比 72.53%
- 总股本 1.12亿
- 历史最高 32.88
- 量 比 0.74
- 振 幅 4.01%
- 历史最低 5.6326
- 每 手 1
- 风险率 4.43%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'Biotech Says Its Cholesterol Drug Shows Signs Of Preventing Alzheimer's; NewAmsterdam Pharma Hopes Medicine Born Out Of Big Failures May Have An Unexpected Benefit' - STAT News
https://www.statnews.com/2025/07/30/new-amsterdam-pharma-cholesterol-drug-alzheimers/
07-30 20:25
NewAmsterdam Pharma to Present Alzheimer’s Biomarker Data from BROADWAY Trial at AAIC 2025
New Amsterdam Pharma will host a conference call and webcast on July 30, 2025, at 10:00 a.m. ET to discuss Alzheimer's Disease biomarker data from the BROADWAY clinical trial. Featured speakers include Philip Scheltens, M.D., Ph.D., Kellyann Niotis, M.D., and Nathaniel Chin, M.D.
07-22 12:00
Goldman Sachs Initiates Coverage On NewAmsterdam Pharma Co with Neutral Rating, Announces Price Target of $27
Goldman Sachs analyst Asad Haider initiates coverage on NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Neutral rating and announces Price Target of $27.
07-17 19:21
NewAmsterdam Pharma Updates Employment Agreement with Executive
The latest update is out from NewAmsterdam Pharma Company ( ($NAMS) ). On July ...
07-12 04:48
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
美股大行评级 | 潜在涨幅40%！华兴资本首予Coinbase买入评级，目标价353.3！Sarepta治疗遭多家机构下调评级和目标价！
06-18 09:46
美股大行评级 | 潜在涨幅超50%，数十家机构大幅上调甲骨文目标价！
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1140203048973164544.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Maxim Group：上调Datavault AI(DVLT)评级至"买入"，目标价3美元</p> <p>• 蒙特利尔银行：维持DoubleVerify Holdings(DV)"跑赢大市"评级，目标价从25美元升至26
06-13 09:33
What Analysts Are Saying About NewAmsterdam Pharma Co Stock
4 analysts have shared their evaluations of NewAmsterdam Pharma Co (NASDAQ:NAMS...
06-12 21:01
Needham Reiterates Buy on NewAmsterdam Pharma Co, Maintains $40 Price Target
Needham analyst Serge Belanger reiterates NewAmsterdam Pharma Co (NASDAQ:NAMS) with a Buy and maintains $40 price target.
06-12 18:29
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
Analyst Says NewAmsterdam Stock Has Over 100% Upside, Citing 90% Success Probability For Obicetrapib
NewAmsterdam shared new Phase 3 data showing obicetrapib reduced LDL-C by 33% and impacted Alzheimer's biomarkers ahead of July 2025 presentation.
06-10 00:23
